Genetic variation in organic cation transporters and considerations in drug development
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic variation in organic cation transporters and considerations in drug development
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 19, Issue 3, Pages 149-164
Publisher
Informa UK Limited
Online
2023-04-18
DOI
10.1080/17425255.2023.2202813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing Diversity and Inclusion in Clinical Trials
- (2023) Amy Corneli et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Relationships between Inhibition, Transport and Enhanced Transport via the Organic Cation Transporter 1
- (2022) Ole Jensen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance
- (2022) Maciej J. Zamek‐Gliszczynski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical implications of altered drug transporter abundance/function and PBPK modeling in specific populations: An ITC perspective
- (2022) Xiaoyan Chu et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Relevance of Organic Anion Transporting Polypeptide 1B –Mediated Hepatic Uptake for High‐Permeability Drugs: A Perspective
- (2022) Manthena V.S. Varma CLINICAL PHARMACOLOGY & THERAPEUTICS
- Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures
- (2022) A.D. Rodrigues CLINICAL PHARMACOLOGY & THERAPEUTICS
- Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
- (2022) Anne T. Nies et al. PHARMACOLOGY & THERAPEUTICS
- Structural basis of organic cation transporter-3 inhibition
- (2022) Basavraj Khanppnavar et al. Nature Communications
- Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?
- (2021) Christoph Wenzel et al. Frontiers in Pharmacology
- Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport
- (2021) Ole Jensen et al. Frontiers in Pharmacology
- Analysis of OCT1, OCT2 and OCT3 gene polymorphisms among Type 2 diabetes mellitus subjects in Indian ethnicity, Malaysia
- (2021) Sabah Ghasan Abood Al-Ashoor et al. SAUDI JOURNAL OF BIOLOGICAL SCIENCES
- The L125F MATE1 variant enriched in populations of Amerindian origin is associated with increased plasma levels of metformin and lactate
- (2021) Monserrat I. Morales-Rivera et al. BIOMEDICINE & PHARMACOTHERAPY
- Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
- (2021) Gonzalo Villapalos-García et al. Frontiers in Pharmacology
- Serotonin homeostasis in the materno‐foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO‐A) in uptake and degradation of serotonin by human and rat term placenta
- (2020) Rona Karahoda et al. Acta Physiologica
- Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)
- (2020) Sumathy Mathialagan et al. BIOCHEMICAL PHARMACOLOGY
- Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far?
- (2020) Ravindra V. Alluri et al. Expert Opinion on Drug Metabolism & Toxicology
- A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker
- (2020) Lina Luo et al. ANALYTICAL CHEMISTRY
- Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers
- (2020) Takeshi Miyake et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition
- (2020) Zulfan Zazuli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting
- (2020) Kim Huard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Intracellular β 1 -Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility
- (2020) Ying Wang et al. CIRCULATION RESEARCH
- PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations
- (2019) Kunal Taskar et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative Proteomics and Mechanistic Modeling of Transporter‐mediated Disposition in Non‐Alcoholic Fatty Liver Disease
- (2019) Anna Vildhede et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-mediated Uptake
- (2019) Bridget L. Morse et al. DRUG METABOLISM AND DISPOSITION
- rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response
- (2019) Khaled Naja et al. Drug Metabolism and Pharmacokinetics
- Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
- (2019) Muhammad Rafehi et al. Frontiers in Pharmacology
- The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
- (2018) Petra Belohlavkova et al. Archives of Medical Science
- OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil
- (2018) Johannes Matthaei et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity
- (2018) Dong Guo et al. PHARMACEUTICAL RESEARCH
- Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study
- (2018) David Hahn et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- OCT3 promoter haplotype is associated with metformin pharmacokinetics in Koreans
- (2018) Eun Young Kwon et al. Scientific Reports
- Transporters Involved in Metformin Pharmacokinetics and Treatment Response
- (2017) Xiaomin Liang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics
- (2016) J Matthaei et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model
- (2016) G Patilea-Vrana et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics
- (2016) B Prasad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients
- (2016) Linda Zaharenko et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics
- (2016) David J. Wagner et al. PHARMACOLOGICAL RESEARCH
- Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans
- (2015) J. Oh et al. DIABETES OBESITY & METABOLISM
- SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients
- (2015) Rui He et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers
- (2015) Mette Marie Hougaard Christensen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Role of organic cation transporters in drug–drug interaction
- (2015) Hermann Koepsell Expert Opinion on Drug Metabolism & Toxicology
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
- (2015) Manthena V. Varma et al. PHARMACEUTICAL RESEARCH
- Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity
- (2015) Claudia Lanvers-Kaminsky et al. PHARMACOGENOMICS
- Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers
- (2014) Sung Kweon Cho et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine
- (2014) Susanne Johansson et al. CLINICAL PHARMACOKINETICS
- Taste of a Pill
- (2014) Nora Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
- (2014) A Di Paolo et al. PHARMACOGENOMICS JOURNAL
- The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
- (2014) Jian Zong et al. Journal of the International AIDS Society
- Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects
- (2013) Hwa Yoon et al. AAPS Journal
- Role of Hepatic Efflux Transporters in Regulating Systemic and Hepatocyte Exposure to Xenobiotics
- (2013) Nathan D. Pfeifer et al. Annual Review of Pharmacology and Toxicology
- Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration
- (2013) Mladen V. Tzvetkov et al. BIOCHEMICAL PHARMACOLOGY
- Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
- (2013) Barbara Grün et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium
- (2013) K M Hillgren et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Identification of Novel Substrates and Structure–Activity Relationship of Cellular Uptake Mediated by Human Organic Cation Transporters 1 and 2
- (2013) Ramon Hendrickx et al. JOURNAL OF MEDICINAL CHEMISTRY
- A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin
- (2013) Mette M.H. Christensen et al. Pharmacogenetics and Genomics
- OCT1 genetic variants influence the pharmacokinetics of morphine in children
- (2013) Tsuyoshi Fukuda et al. PHARMACOGENOMICS
- Structures of a Na+-coupled, substrate-bound MATE multidrug transporter
- (2013) M. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)
- (2013) Qing Li et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms
- (2012) Kenta Yoshida et al. Annual Review of Pharmacology and Toxicology
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
- (2012) Yoshihisa Shitara et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K)
- (2012) S Ito et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomic association between a variant inSLC47A1gene and therapeutic response to metformin in type 2 diabetes
- (2012) I. Tkáč et al. DIABETES OBESITY & METABOLISM
- Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development
- (2012) Yurong Lai et al. Expert Opinion on Drug Metabolism & Toxicology
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
- (2012) Matthias B. Wittwer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug transport by Organic Anion Transporters (OATs)
- (2012) Gerhard Burckhardt PHARMACOLOGY & THERAPEUTICS
- Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics
- (2011) Atsushi Yonezawa et al. BRITISH JOURNAL OF PHARMACOLOGY
- Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol
- (2011) M V Tzvetkov et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin
- (2011) J H Choi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects
- (2011) H Kusuhara et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study
- (2011) K Maeda et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Human metabolic individuality in biomedical and pharmaceutical research
- (2011) Karsten Suhre et al. NATURE
- The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
- (2011) Mette M.H. Christensen et al. Pharmacogenetics and Genomics
- Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect ofERCC1polymorphisms
- (2011) Mladen V Tzvetkov et al. PHARMACOGENOMICS
- Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity
- (2010) Takanori Nakamura et al. BIOCHEMICAL PHARMACOLOGY
- Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl- -D-Glucosaminidase
- (2010) R. M. Franke et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer
- (2010) Fiona H. Blackhall et al. Journal of Thoracic Oncology
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
- (2010) Zhi-Jun Wang et al. Pharmacogenetics and Genomics
- Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients
- (2010) Kana Toyama et al. Pharmacogenetics and Genomics
- Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin
- (2010) Ligong Chen et al. Pharmacogenetics and Genomics
- Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron
- (2010) M V Tzvetkov et al. PHARMACOGENOMICS JOURNAL
- Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2
- (2009) Yuko Tanihara et al. BIOCHEMICAL PHARMACOLOGY
- Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
- (2009) K K Filipski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
- (2009) M V Tzvetkov et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study
- (2009) M. L. Becker et al. DIABETES
- Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser
- (2009) O. Zolk et al. DRUG METABOLISM AND DISPOSITION
- In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
- (2009) Hiroyuki Kusuhara et al. Drug Metabolism and Pharmacokinetics
- Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
- (2009) Anne T. Nies et al. HEPATOLOGY
- Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells
- (2009) M. Tsuda et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
- (2009) Ying Chen et al. Pharmacogenetics and Genomics
- Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
- (2009) Matthijs L. Becker et al. Pharmacogenetics and Genomics
- Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function
- (2009) Ying Chen et al. PHARMACOGENOMICS JOURNAL
- Interaction of Cisplatin with the Human Organic Cation Transporter 2
- (2008) K. K. Filipski et al. CLINICAL CANCER RESEARCH
- Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
- (2008) IS Song et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine
- (2008) S. Matsushima et al. DRUG METABOLISM AND DISPOSITION
- Polymorphism in human organic cation transporters and metformin action
- (2008) Hiroshi Takane et al. PHARMACOGENOMICS
- Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics
- (2008) Y. Moriyama et al. XENOBIOTICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now